In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Artelo Biosciences (ARTL – Research Report), with a price target of $40.00. The company’s shares closed yesterday at $1.69.
Higgins covers the Healthcare sector, focusing on stocks such as SCYNEXIS, Achieve Life Sciences, and Palatin Technologies. According to TipRanks, Higgins has an average return of 3.1% and a 32.19% success rate on recommended stocks.
Artelo Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.
See the top stocks recommended by analysts >>
ARTL market cap is currently $4.83M and has a P/E ratio of -0.48.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Artelo Biosciences, Inc. is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company was founded by James Manley on May 2, 2011 and is headquartered in San Diego, CA.
Read More on ARTL:
- Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
- Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
- Artelo Biosciences initiates Phase 2a portion of CAReS trial of ART27.13
- Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update
- Artelo Biosciences expects cash to fund operations into 2H24
